F10 and coronary artery disorder: Now, we could further speculate that FVIIa–AT assessment may allow the identification of the subgroup of stable CAD patients who can have the major benefit from a more aggressive antithrombotic treatment associating antiplatelet agents and FXa-inhibitors (Figure 4).